Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Medtronic
Fish and Richardson
Accenture
Daiichi Sankyo
Colorcon
QuintilesIMS
UBS
Farmers Insurance

Generated: December 19, 2018

DrugPatentWatch Database Preview

REQUIP XL Drug Profile

« Back to Dashboard

When do Requip Xl patents expire, and when can generic versions of Requip Xl launch?

Requip Xl is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There are two patents protecting this drug and seven Paragraph IV challenges.

This drug has fifty patent family members in twenty-seven countries.

The generic ingredient in REQUIP XL is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

Drug patent expirations by year for REQUIP XL
Pharmacology for REQUIP XL
Drug ClassNonergot Dopamine Agonist
Mechanism of ActionDopamine Agonists
Synonyms for REQUIP XL
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
374R208
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-(2-(Dipropylamino)ethyl)indolin-2-one hydrochloride
4-(2-(Dipropylamino)ethyl)indolin-2-onehydrochloride
4-(2-di-n-propylaminoethyl)-2(3H)-indolone hydrochloride
4-(2-di-n-propylaminoethyl)-2(3H)indolone hydrochloride
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one hydrochloride
4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone Hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]indolin-2-one hydrochloride
4CA-1107
91374-20-8
91374-20-8,91374-21-9(freebase)
91374-21-9 (base)
91374-21-9 (Parent)
A843815
AB0009822
ABP000199
AC-735
AC-736
AC1L2ABS
AC1Q3EQJ
ACT02690
Adartrel
AK-59618
AKOS015844988
AN-15584
ANW-58872
BC207366
BS-1020
CCG-213346
CHEBI:8889
CHEMBL1200411
CS-2864
CTK8B7890
D00784
D7ZD41RZI9
DTXSID50238533
EBD38503
EU-0101101
FC0024
FT-0642200
HP-3000
HY-B0623A
I06-0693
JZP-7
KB-80420
KS-000011L6
KS-00002WRZ
LP01101
LS-83828
M-1298
MCULE-8190476072
MFCD01754173
MLS003899234
MolPort-003-987-439
NCGC00094373-01
NCGC00261786-01
NP-201
NVD-434
R 4152
Repreve
Requip (TN)
ReQuip LP
ReQuip PR
ReQuip XR
Ropinirole (hydrochloride)
Ropinirole for peak identification 1, EuropePharmacopoeia (EP) Reference Standard
Ropinirole for peak identification 2, EuropePharmacopoeia (EP) Reference Standard
Ropinirole HCl
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN:USP]
Ropinirole hydrochloride [USAN]
Ropinirole hydrochloride, EuropePharmacopoeia (EP) Reference Standard
Ropinirole Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur
Ropinirole hydrochloride, powder, >=98% (HPLC)
Ropinirole hydrochloride, United States Pharmacopeia (USP) Reference Standard
Ropinirole hydrochloride;
Ropinirole hydrochloride/
Ropinirolehydrochloride
Ropinirolhydrochloride
s3189
SCHEMBL40760
SK&F 101468-A
SK&F-101468-A
SK&F-101468A
SKF 101468 hydrochloride
SKF 101468; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
SKF-101468A
SMR001456484
SR-01000076215
SR-01000076215-2
ST24042825
ST51051236
TC-030791
TL8005858
Tox21_501101
UNII-D7ZD41RZI9
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Z1695926158

US Patents and Regulatory Information for REQUIP XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for REQUIP XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-004 Jun 13, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for REQUIP XL
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 6 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 12 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 8 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 4 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 2 mg ➤ Subscribe ➤ Try a Free Trial

International Patents for REQUIP XL

Country Document Number Estimated Expiration
Italy MI20000852 ➤ Try a Free Trial
Israel 152184 ➤ Try a Free Trial
Slovenia 1272167 ➤ Try a Free Trial
South Korea 20070065922 ➤ Try a Free Trial
South Africa 200209226 ➤ Try a Free Trial
China 1198598 ➤ Try a Free Trial
European Patent Office 1681051 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for REQUIP XL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/040 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ROPINIROLE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: UK 10592/0085 19960702
C0036 Belgium ➤ Try a Free Trial PRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Medtronic
Fish and Richardson
Accenture
Daiichi Sankyo
Colorcon
QuintilesIMS
UBS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.